{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:16:45Z","timestamp":1788193005791,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.japh.2026.103156","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:21:55Z","timestamp":1780503715000},"page":"103156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-108X","authenticated-orcid":false,"given":"Kenneth L.","family":"McCall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5132-5313","authenticated-orcid":false,"given":"Sarah E.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6830-6966","authenticated-orcid":false,"given":"Elizabeth A.","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.japh.2026.103156_bib1","first-page":"367","article-title":"Pharmaceutical compounding: the oldest, most symbolic, and still vital part of pharmacy","volume":"20","author":"Kochanowska-Karamyan","year":"2016","journal-title":"Int J Pharm Compd"},{"issue":"9","key":"10.1016\/j.japh.2026.103156_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/ph15091091","article-title":"The Role of Pharmaceutical Compounding in Promoting Medication Adherence","volume":"15","author":"Carvalho","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.japh.2026.103156_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13181-020-00814-3","article-title":"Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors","volume":"17","author":"Watson","year":"2021","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.japh.2026.103156_bib4","series-title":"Compounding and the FDA: questions and answers","year":"2024"},{"issue":"3","key":"10.1016\/j.japh.2026.103156_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/PTS.0000000000000188","article-title":"US compounding pharmacy-related outbreaks, 2001-2013: public health and patient safety lessons learned","volume":"14","author":"Shehab","year":"2018","journal-title":"J Patient Saf"},{"issue":"4","key":"10.1016\/j.japh.2026.103156_bib6","first-page":"178","article-title":"Risk and liabilities of prescribing compounded medications","volume":"126","author":"Randell","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.japh.2026.103156_bib7","series-title":"Food and Drug Administration Modernization Act, Pub L No. 105-115","year":"1997"},{"key":"10.1016\/j.japh.2026.103156_bib8","series-title":"Thompson v Western States Medical Center, 535 US 357","year":"2002"},{"key":"10.1016\/j.japh.2026.103156_bib9","series-title":"Drug Quality and Security Act, Pub L No. 113-54","year":"2013"},{"issue":"6","key":"10.1016\/j.japh.2026.103156_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ajhp\/zxae271","article-title":"Considerations for developing a health-system 503B outsourcing strategy","volume":"82","author":"Pamphile","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2026.103156_bib11","series-title":"Warning letters","year":"2025"},{"key":"10.1016\/j.japh.2026.103156_bib12","series-title":"ICH Q9(R1) Quality Risk Management","year":"2023"},{"key":"10.1016\/j.japh.2026.103156_bib13","series-title":"Registered outsourcing facilities","year":"2025"},{"key":"10.1016\/j.japh.2026.103156_bib14","series-title":"Inspections","year":"2025"},{"key":"10.1016\/j.japh.2026.103156_bib15","series-title":"Coronavirus (COVID-19) update: FDA outlines inspection and assessment activities during pandemic, roadmap for future state of operations. News release","year":"2021"},{"key":"10.1016\/j.japh.2026.103156_bib16","series-title":"Drug safety: FDA should implement strategies to retain its inspection workforce","year":"2024"},{"key":"10.1016\/j.japh.2026.103156_bib17","series-title":"State-by-State Patchwork Creates Onerous Burdens for 503B Outsourcing Facilities","year":"2022"},{"issue":"4","key":"10.1016\/j.japh.2026.103156_bib18","first-page":"298","article-title":"The role of compounding pharmacists during drug shortages","volume":"26","author":"Ofei","year":"2022","journal-title":"Int J Pharm Compd"},{"issue":"4","key":"10.1016\/j.japh.2026.103156_bib19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s43441-019-00015-3","article-title":"A quantitative study of US FDA inspection data for drug manufacturing sites","volume":"54","author":"Pazhayattil","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.japh.2026.103156_bib20","series-title":"Pharmaceutical inspections and compliance: current good manufacturing practice (CGMP) inspections and compliance","year":"2024"},{"issue":"6","key":"10.1016\/j.japh.2026.103156_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103993","article-title":"A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023","volume":"29","author":"Patel","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.japh.2026.103156_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12247-024-09879-x","article-title":"An Analysis of FDA Warning Letter Citations from 2019-2023","volume":"19","author":"Kwiecinski","year":"2024","journal-title":"J Pharm Innov"},{"key":"10.1016\/j.japh.2026.103156_bib23","series-title":"Fact sheet: HHS\u2019 transformation to make America healthy again","year":"2025"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912600141X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912600141X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:38:29Z","timestamp":1788190709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431912600141X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S154431912600141X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103156","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103156"}}